Drug intelligence / Profile preview

LY4065967

Development stage: Phase 2
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Oral

Overview

LY4065967 is an investigational small molecule drug developed by Eli Lilly for an undisclosed indication. As of 2025, it is in early clinical development, with phase 1 trials conducted in healthy volunteers to assess safety, tolerability, and pharmacokinetics. The specific mechanism of action and therapeutic target have not been disclosed publicly. No approved indications or known adverse events are reported at this stage.

Other names: LY-4065967LY4065967LY 4065967

Beyond the preview

Go deeper on LY4065967.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY4065967.

Explore the full profile